



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/743,884
Filing Date	December 22, 2003
First Named Inventor	Yizhong Gu
Art Unit	1645
Examiner Name	Not yet assigned
Attorney Docket Number	01492.US1

ENCLOSURES (Check all that apply)

- | | | |
|---|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment/Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input checked="" type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation
Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input type="checkbox"/> Other Enclosure(s) (please identify below): |
|---|---|--|

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Pharmacia & Upjohn Company Edward F. Rehberg 34,703
Signature	<i>Edward F. Rehberg</i>
Date	6-3-04

CERTIFICATE OF TRANSMISSION/MAILING


I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Valerie L. Schipper
Signature	<i>Valerie L. Schipper</i>

Date 6-3-2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**180.00**

Complete if Known

Application Number	10/743,884
Filing Date	December 22, 2003
First Named Inventor	Yizhong Gu
Examiner Name	Not yet assigned
Art Unit	1645
Attorney Docket No.	01492.US1

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

21-0718

Pharmacia & Upjohn Company

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments

☐ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	180	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$)**0.00**

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

		Extra Claims		Fee from below		Fee Paid
Total Claims		-20** =	0	X	\$0.00	
Independent Claims		-3** =	0	X	\$0.00	
Multiple Dependent					\$0.00	

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)**0.00**

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**180.00**

SUBMITTED BY

Name (Print/Type) **Edward F. Rehberg**

Registration No. **34,703**
(Attorney/Agent)

(Complete (if applicable))

Telephone **(269) 833-7829**

Signature

Date

6-03-04


WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

06/08/2004 LUONDIN1 00000044 210718 10743884

01 FC:1806



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	Atty. Docket No. 01492.US1	Serial No. 10/743,884
	Applicant Yizhong Gu	
	Filing Date December 22, 2003	Group 1645

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA	4,366,241	Dec. 28, 1982	Tom, et. al.	435	7	
	AB	4,376,110	March 8, 1983	David, et. al.	436	513	
	AC	4,517,288	May 14, 1985	Giegel, et. al.	435	7	
	AD	4,837,168	June 6, 1989	De Jaeger, et. al.	436	533	
	AE	5,118,937	June 2, 1992	Hillenkamp et. al.	250	282	
	AF	5,514,545	May 7, 1996	Rosenstein	436	514	
	AG	5,591,645	Jan. 7, 1997	Eberwine	435	6	
	AH	5,622,871	Apr. 22, 1997	May, et. al.	436	514	
	AI	5,719,060	Feb. 17, 1998	Hutchens, et. al.	436	174	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	AJ	WO 91/09955	July 11, 1991	WIPO	C12N	15/67	X	
	AK	WO 91/18982	Dec 12, 1991	WIPO	C12N	15/12	X	
	AL	WO 92/20808	Nov. 26, 1992	WIPO	C12N	15/85	X	
	AM	WO 93/11236	June 10, 1993	WIPO	C12N	15/13	X	
	AN	WO 94/12650	June 9, 1994	WIPO	C12N	15/90	X	
	AO	WO 95/35505	Dec. 28, 1995	WIPO	G01N	33/543	X	
	AP	WO 97/09433	Mar. 13, 1997	WIPO	C12N	15/54	X	
	AQ	EP A 0367566	May 14, 1997	Europe	C12N	15/12	X	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AR	Smith, T.F., and M.S. Waterman, "'Comparison OF Biosequences," in <u>Advances in Applied Mathematics</u> 2, pp. 482-489, 1981.
	AS	Asai, ed. <u>Methods in Cell Biology</u> Volume 37, Chapters 6, 7, &8; <u>Antibodies in Cell Biology</u> , Academic Press, Inc. New York (1993)
	AT	Aujame et al., <u>Human Antibodies</u> , 8(4):155-168 (1997);
	AU	Ausubel et al., eds., <u>Current Protocols in Molecular Biology</u> , Section 10.11.8, John Wiley & Sons, New York 1993

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No. 01492.US1	Serial No. 10/743,884
		Applicant Yizhong Gu	
		Filing Date 2003	December 22, Group 1645
	AV	Ausubel et al., eds., Current Protocols in Molecular Biology, Chapter 11, John Wiley & Sons, New York 1993	
	AW	Ausubel, et.al. (Eds.), Protocols in Molecular Biology, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10.	
	AX	Bolton and Hunter, Biochem. J. 133, 529 (1973)	
	AY	Bruggemann and Neuberger, Immunol. Today, 17(8):391-97 (1996)	
	AZ	Bruggemann and Taussig, Curr. Opin. Biotechnol., 8:455-58 (1997)	
	BA	Capecchi, Science 244:1288-1292 (1989)	
	BB	Choo et al., (1997) J Mol Biol 273:525-32	
	BC	Cole et al., pg. 77-96 in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985)	
	BD	Cosman <i>et al.</i> (Nature 312:768 (1984)	
	BE	Cosman <i>et al.</i> (Mol. Immunol. 23:935 (1986)	
	BF	Dayhoff, in Atlas of Protein Sequence and Structure, Vol. 5, p. 124, National Biochemical Research Foundation, Washington, D.C. (1972)	
	BG	Evan et al., Molecular and Cellular Biology, 5:3610-3616 (1985)	
	BH	Field et al., Mol. Cell. Biol., 8:2159-2165 (1988)	
	BI	Gluzman <i>et al.</i> , Cell 23:175 (1981)	
	BJ	Greisman and Pabo (1997) Science 275:657-61	
	BK	Harlow et al. (Eds), Antibodies A Laboratory Manual; Cold Spring Harbor Laboratory; Cold Spring Harbor, NY (1988), Chapter 6 and 14	
	BM	Hoefler, G., et. al., cDNA cloning of the human peroxisomal enoyl-CoA hydratase:3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme and localization to chromosome 3q26.3-3q28: a free left Alu arm is inserted in the 3-prime noncoding region. <i>Genomics</i> 19: 60-67, 1994.	
	BN	Hoogenboom, TIBTECH, 15:62-70, 1997.	
	BO	Hopp, et. al., BioTechnology, 6:1204-1210, 1988.	
	BP	Hopp and Woods, Mol. Immunol, 1983, 20(4): p. 483-489	
	BQ	Hopp and Woods, Proc. Natl. Acad. Sci. USA 1981, 78(6) p. 3824-3828	
	BR	Innis, M.A., PCR Protocols: A Guide to Methods and Applications, David H. Gelfand, John J. Sninsky, and Thomas J. White, eds., Academic Press, Inc., New York, 1990.	
	BS	Kim et al., (1997) Proc Natl Acad Sci USA 94:3616-3620	
	BT	Kohler, G. and Milstein, C., Nature 256: 495-497 (1975)	
	BU	Kozbor et al., Immunology Today 4: 72 (1983)	
	BV	Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY:NY (1975), pp.71-77	

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>		Atty. Docket No. 01492.US1	Serial No. 10/743,884
		Applicant Yizhong Gu	
		Filing Date December 22, 2003	Group 1645
	BW	Liu et al., (1997) Proc Natl Acad Sci USA 94:5525-30	
	BX	Luckow and Summers, <i>BioTechnology</i> 6:47 (1988)	
	BY	Lutz-Freyermuth et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397(1990)	
	BZ	Maddox et al., 1983, J. Exp. Med., 158:1211	
	CA	Margalit, H. et al., J. Immunol. 1987 138(7): pg 2213-29	
	CB	Martin et al., Science, 255:192-194 (1992)	
	CC	McColl et al., (1999) Proc Natl Acad Sci USA 96:9521-6	
	CD	Morrison, Methods in Enzymology 32b, 103 (1974)	
	CE	Okayama and Berg (<i>Mol. Cell. Biol.</i> 3:280 (1983));	
	CF	Paborsky et al., Protein Engineering, 3(6):547-553 1990	
	CG	Qi, C., et. al., Absence of spontaneous peroxisome proliferation in enoyl-CoA hydratase/L-3-hydroxyacyl-CoA dehydrogenase-deficient mouse liver: further support for the role of fatty acyl CoA oxidase in PPAR-alpha ligand metabolism. <i>J. Biol. Chem.</i> 274: 15775-15780, 1999	
	CH	Rader et al., Curr. Opin. Biotechnol., 8:503-508 (1997)	
	CI	Rattan et al., "Protein Synthesis: Post-translational Modifications and Aging", Ann NY Acad Sci (1992) 663:4842	
	CJ	Sambrook, et al., (Eds.), Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.	
	CK	Segal et al., (1999) Proc Natl Acad Sci USA 96:2758-2763	
	CL	Seifter et al., "Analysis for protein modifications and nonprotein cofactors", Meth Enzymol (1990) 182:626-646	
	CM	Skinner et al., J. Biol. Chem., 266:14163-14166 (1991)	
	CN	Stites & Terr, eds. Basic and Clinical Immunology 7th Edition, Chapter 18, (1991)	
		Syvanen et al., J. Biol. Chem. 284, 3762 (1973)	
	CO	Tijssen, P. (1993) Laboratory Techniques in Biochemistry and Molecular Biology: Hybridization With Nucleic Acid Probes, Part I. Theory and Nucleic Acid Preparation, Chapter 3, Elsevier, New York, N.Y	
	CP	Wanders, R. J. A, et. al., A bifunctional protein with deficient enzymic activity: identification of a new peroxisomal disorder using novel methods to measure the peroxisomal beta-oxidation enzyme activities. <i>J. Inherit. Metab. Dis.</i> 13: 375-379, 1990.	
	CQ	Watkins, P. A., et. al., Peroxisomal bifunctional enzyme deficiency. <i>J. Clin. Invest.</i> 83: 771-777, 1989.	
	CR	Wold, F., Post-translational Protein Modifications: Perspectives and Prospects, pgs. 1-12 in Postranslational Covalent Modification of Proteins, B. C. Johnson, Ed., Academic Press, New York, 1983	
	CS	Wu et al., (1995) Proc Natl Acad Sci USA 92:344-348	
Examiner		Date Considered	